Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Arrowhead Research   /   Forum Arrowhead Research geopend

Aandeel Arrowhead Pharmaceuticals OTC:ARWR.Q, US04280A1007

Vertraagde koers (usd) Verschil Volume
26,070   -0,270   (-1,03%) Dagrange 26,005 - 26,990 1.656.104   Gem. (3M) 1,3M

Forum Arrowhead Research geopend

Volgen
8.628 Posts
Pagina: «« 1 ... 242 243 244 245 246 ... 432 »» | Laatste | Omlaag ↓
  2. forum rang 6 Tom3 27 oktober 2021 16:15
    quote:

    Hulskof schreef op 27 oktober 2021 15:46:

    www.verywellhealth.com/c3-complement-...

    C3 vereenvoudigd.
    Low C3 level can occur with:
    SLE
    Infections
    Liver failure
    Kidney failure
    Lupus nephritis
    C3 glomerulopathy5
    Organ transplant rejection

    High C3 levels can occur with:
    Cancer
    Ulcerative colitis

    Het lijkt me toch de doelstelling van rnai om te voorkomen dat er teveel van die C3 eiwitten ontstaan, Nou ja ik zal mer er nog eens in verdiepen.

    Cancer
    Ulcerative colitis
  5. forum rang 5 Hulskof 27 oktober 2021 20:14
    Arrowhead Pharma thesis revisited at Cantor after KOL event

    Arrowhead Pharmaceuticals (NASDAQ:ARWR) held a key opinion leader (KOL) webinar on Tuesday to discuss its RNA interference ((RNAi)) candidate, ARO-C3, being developed for multiple indications involving the complement system.
    The potential targets include IgA nephropathy ((IgAN)), C3 glomerulopathy (C3G), and paroxysmal nocturnal hemoglobinuria (PNH).
    As the company draws up plans to initiate the dosing in a Phase 1/2a study for ARO-C3 in Q1 2022, Cantor Fitzgerald analyst Alethia Young expects the candidate to bring further valuation upside for the firm’s current valuation for the stock.
    Cantor has an Overweight rating on the stock and the price target of $79 per share implies a premium of ~19.5% to the last close.
    “We believe the study sets up the company to quickly evaluate which indication or indications of ARO-C3 may be most active, and decide which dose is most tolerable/effective to take to late-stage development,” she wrote in a note on Tuesday.
    The candidate could have “a potentially quick-to-market opportunity,” in IgAN and C3G, Young argued, citing the lack of approved standard of care treatments for the indications.
    While C5 inhibitors, Soliris and Ultomiris from AstraZeneca (NASDAQ:AZN), dominate the PNH market, the analyst notes an opportunity for Arrowhead (ARWR) to differentiate the dosing frequency for the condition with ARO-C3. Also notes that with C3 inhibition being validated target, the company can de-risk the asset.
    Alexion which was acquired by Astra (AZN) this year, made over $5B in net sales from Soliris and Ultomiris in 2020.
  9. forum rang 6 Tom3 29 oktober 2021 10:29
    www.bbc.com/news/health-58988006

    Gezien op het Twitter account van de door mij zeer gewaardeerde Aspector:

    [But] if we can control genes and switch them on and off when we want to, then almost anything is possible in terms of treating diseases including Alzheimer's and cancer and everything else," Prof Rees said.

    Gene-silencing has already proven effective in other rare genetic diseases such as amyloidosis. Its ability to tweak how DNA works in the human body, without permanently altering it, has already seen it used as a twice-a-year cholesterol busting jab.

    Tara Moore, a professor of personalised medicine at the University of Ulster, said gene silencing had the potential to be as big as antibiotics.

    She told BBC Radio 4's Inside Health: "It will be, it's a very powerful tool, it is so specific, it's really phenomenal.
  10. forum rang 5 Piddy 1 november 2021 12:57
    Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences
    Nov 1, 2021 at 7:30 AM EDT

    PASADENA, Calif.--(BUSINESS WIRE)--Nov. 1, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

    The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) – November 12-15, 2021

    Title: ARO-AAT Treatment Reduces Intra-hepatic Z-AAT Leading to Improved Parameters of Liver Health and Fibrosis Regression
    Authors: Pavel Strnad, et al.
    Publication Number: LP11
    Session: Late-breaking Abstract Posters

    Title: ARO-HSD, An Investigational RNAi Therapeutic, Demonstrates Reduction in ALT and Hepatic HSD17B13 mRNA and Protein in Patients with NASH or Suspected NASH
    Authors: Lung-Yi Mak, et al.
    Publication Number: LP13
    Session: Late-breaking Abstract Posters

    Title: Efficacy and Safety of the siRNA JNJ-3989 and/or the Capsid Assembly Modulator (CAM) JNJ-6379 for the Treatment of Chronic Hepatitis B Virus Infection (CHB): Results from the Phase 2B REEF-1 Study
    Authors: Man Fung Yuen, et al.
    Publication Number: LO10
    Session: Late Breaking Session 2

    American Heart Association (AHA) Scientific Sessions 2021 – November 13-17, 2021

    Title: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia
    Authors: Christie Ballantyne, presenting on behalf of Peter Clifton, et al.
    Session: The Future of Lipidology: Novel and Emerging Interventions for Lipid Disorders

    Jefferies London Healthcare Conference – November 16-19, 2021

    November 16, 2021, 3:50 p.m. GMT – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation

    Piper Sandler 33rd Annual Healthcare Conference – November 30-December 2, 2021

    November 30, 2021 – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation

    A copy of the presentation materials and/or live webcast links may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

  15. forum rang 5 Hulskof 1 november 2021 15:46
    quote:

    Tom3 schreef op 1 november 2021 15:27:

    Wat een koersgeweld (ondanks nog steeds een magere omzet). Mijn A-team (Arrowhead, Affimed en Adaptimmune) doet het vandaag Geweldig!

    www.youtube.com/watch?v=wyz_2DEah4o
    Arrowhead gaat idd hard. :-)
    Zou mooi zijn als we dit jaar de 100 nog weten aan te tikken.
  16. forum rang 5 Piddy 1 november 2021 16:00
    Dan gaat mijn alert nog enkele keren afgaan.
    Ik heb het geluid al wat minder gezet in de veronderstelling dat het van dat zal zijn.

    Technisch is het best mogelijk.
    Niet naar analyse toe maar de binnenkomende info onder de titels alleen al lijkt toch ferme vuurkracht te gaan bevatten.

    Dan de aankondiging van een fase 3 en als toetje wat nieuwe analisten die het eindelijk snappen waar ARWR echt voor staat.
    Voor mijn en jullie part mag Bioboyscout gelijk krijgen over heel de lijn maar samen met jullie willen we het hier vooral in de data zien.

    Succes!
  18. Wil Helmus 1 november 2021 17:31
    Results: Patients in REEF-1 were 66% male, 52% White, 41% Asian, 70% HBeAg negative, and 63% VS at baseline (BL). The proportions of patients achieving primary endpoint are depicted in the Figure, with the highest proportion (19.1%) in the JNJ-3989 200mg + NA arm. The JNJ-3989 200mg + NA arm had the highest proportion of patients (33%) achieving HBsAg levels <10 IU/mL by Week 44, and 72% reached <100 IU/mL. Significant mean log10 reductions from baseline to end of treatment in HBsAg were observed with JNJ-3989 200, 100, and 40mg + NA (with dose-response pattern), and JNJ-3989 + JNJ-6379 + NA (–2.58, –2.09, –1.50, and –1.76 log10 IU/mL), but not with PBO or JNJ-6379 + NA (–0.22 and –0.07 log10IU/mL); <3% of patients achieved HBsAg loss. Levels of hepatitis B core-related antigen (HBcrAg), HBV RNA, and HBV DNA (in patients not currently treated at BL), and HBeAg (in HBeAg-positive patients) were reduced on treatment; <1% of patients achieved HBeAg loss. All regimens within this long-term, triple therapy study were generally well tolerated and safe; 2 of 10 reported SAEs (ALT flare and rhabdomyolysis) were considered related to study drug. Treatment discontinuation rates were low (=6.3% in all arms).

    Conclusion: JNJ-3989 showed a dose dependent response with up to 19.1% meeting the primary endpoint at Week 48 compared to 0% in the JNJ-6379 + NA and 2.2% in the PBO + NA arm. Reduction of HBsAg levels was greatest with JNJ-3989 200mg s.c. Q4W + NA.

    www.aasld.org/the-liver-meeting/effic...
  20. forum rang 4 harvester 1 november 2021 18:37
    quote:

    de tuinman schreef op 1 november 2021 18:15:

    Ik vind dit zo'n vreemde manier van berichtgeving. Is dit nu een studie uitslag?
    Waarom wordt er door Arrowhead niet een aparte publicatie voor uitgebracht?

    Hoe zien jullie dit?
    Gewoon een wetenschappelijke presentatie op een wetenschappelijk congres.

    Niets vreemds aan.
8.628 Posts
Pagina: «« 1 ... 242 243 244 245 246 ... 432 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee